Drugs / soy isoflavones
soy isoflavones
also known as
Novasoy · PTI G-2535 · Solgen 40 · Soy germ isoflavones · Soya isoflavones · Soybean isoflavones · Soybean isoflavoues
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00491595 | Mar 2004 → Jul 2005 | poisoning | University of North Carolina | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02007200 | Jul 2009 → Sep 2015 | hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, oropharynx squamous cell carcinoma, tongue carcinoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00205179 | Jan 2005 → Dec 2009 | Alzheimer disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00042380 | Jul 2002 → Apr 2005 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT00029796 | ? → Sep 2003 | chronic renal failure syndrome | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01116310 | Apr 2010 → May 2012 | — | Laboratorios Casen-Fleet S.L.U. | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00277446 | Jan 2006 → Apr 2007 | asthma | Northwestern University | Completed | No outcome recorded |
| — | NCT00203255 | May 2003 → Mar 2005 | migraine disorder | Thomas Jefferson University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01401946 Comparator | May → Oct 2000 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | soy isoflavones | “100mg/day soy isoflavones” NCT00205179 ↗ |
| Known as | Novasoy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00042380 ↗ |
| Known as | PTI G-2535 | “This will be a double blind, Phase I, multiple dose clinical trial of orally administered soy isoflavones (PTI G-2535, 70% unconjugated isoflavones containing genistein,...” NCT00491595 ↗ |
| Known as | Solgen 40 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298060 ↗ |
| Known as | Soy germ isoflavones | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298060 ↗ |
| Known as | Soya isoflavones | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298060 ↗ |
| Known as | Soybean isoflavones | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298060 ↗ |
| Known as | Soybean isoflavoues | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298060 ↗ |
| Action | Inhibit | “intervention with soy isoflavones inhibits NFKB activation and cytokines production” NCT00029796 ↗ |
| Modality | Other / unclassified | “Isoflavones are compounds that occur naturally in soybeans and can be extracted to put in to capsule form or add to foods.” NCT00491595 ↗ |
| Route | Oral | “supplement their diet with a soy isoflavone capsule” NCT00277446 ↗ |